Atacicept Found to Be Safe, with Early Indications of Effectiveness in Lupus Patients
Results from a 24-week Phase 2b study show that atacicept treatment is safe and reduces disease activity and severe flare in systemic lupus erythematosus (SLE) patients, particularly in those with high disease activity or serologically active disease. Results of the ADDRESS II trial (NCT01972568) were published in the study, “…